Tissue Plasminogen Activator

• 

  Subject Areas on Research

  • 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. 
  • A canine model of acute coronary artery thrombosis for the evaluation of reperfusion strategies. 
  • A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. 
  • A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. 
  • A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. 
  • A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. 
  • A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. 
  • Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. 
  • Accelerated TPA for treatment of prosthetic valve thrombosis. 
  • Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction. 
  • Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group. 
  • Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. 
  • Acute ischemic stroke treatment in 2007. 
  • Acute reduction of lipoprotein(a) by tissue-type plasminogen activator. 
  • Acute reduction of lipoprotein(a) by tissue-type plasminogen activator. 
  • Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-hour exclusions and association with outcome: data from Get with the Guidelines-Stroke. 
  • Adoption of thrombolytic therapy in the management of acute myocardial infarction. 
  • Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. 
  • Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. 
  • Alterations in natural anticoagulant levels during allogeneic bone marrow transplantation: a prospective study in 27 patients. 
  • An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke. 
  • An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. 
  • An illuminated cannula for subretinal operations. 
  • An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. 
  • An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. 
  • Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. 
  • Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. 
  • Antifibrinolytic agents reduce tissue plasminogen activator-mediated neuronal toxicity in vitro. 
  • Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy. 
  • Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7. 
  • Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke. 
  • Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. 
  • Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. 
  • Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Atrophie blanche. A disorder associated with defective release of tissue plasminogen activator. 
  • Axonal regrowth after spinal cord injury via chondroitinase and the tissue plasminogen activator (tPA)/plasmin system. 
  • Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. 
  • Behavioral equipoise: a way to resolve ethical stalemates in clinical research. 
  • Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. 
  • Bilateral vitreous hemorrhages as a consequence of thrombolytic therapy successfully treated with vitrectomy in a patient without diabetes. 
  • Binding of tissue-type plasminogen activator to the glucose-regulated protein 78 (GRP78) modulates plasminogen activation and promotes human neuroblastoma cell proliferation in vitro. 
  • Brachial approach to emergency cardiac catheterization during thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. 
  • CT perfusion-guided versus time-guided mechanical recanalization in acute ischemic stroke patients. 
  • Carbon monoxide releasing molecule-2 enhances α2-antiplasmin activity. 
  • Changes in Informed Consent Policy and Treatment Delays in Stroke Thrombolysis. 
  • Changes in standard electrocardiographic ST-segment elevation predictive of successful reperfusion in acute myocardial infarction. 
  • Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. 
  • Chronic kidney disease and bleeding complications after intravenous thrombolytic therapy for acute ischemic stroke. 
  • Chronic kidney disease and stroke. 
  • Clinical Crossroads: a 36-year-old woman recuperating from stroke. 
  • Clinical and economic lessons from studies of coronary thrombolysis. 
  • Clinical outcomes among stroke patients receiving tissue plasminogen activator therapy beyond the 3-hour time window. 
  • Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? 
  • Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke. 
  • Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). 
  • Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery. 
  • Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. 
  • Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. 
  • Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. 
  • Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. 
  • Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. 
  • Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke. 
  • Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). 
  • Comparison of plasminogen binding and activation on extracellular matrices produced by vascular smooth muscle and endothelial cells. 
  • Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. 
  • Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis. 
  • Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction. 
  • Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. 
  • Complement-Dependent Synaptic Uptake and Cognitive Decline after Stroke and Reperfusion Therapy. 
  • Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. TAMI Study Group. 
  • Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. 
  • Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. 
  • Coronary bypass surgery improves global and regional left ventricular function following thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group. 
  • Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. 
  • Correlation of angiographic findings and right (V1 to V3) versus left (V4 to V6) precordial ST-segment depression in inferior wall acute myocardial infarction. 
  • Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. 
  • Current concepts in the management of central retinal vein occlusion. 
  • Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. 
  • Dabigatran-related coagulopathy: when can we assume the effect has "worn off"? 
  • Decreased fibrinolytic activity in porcine-to-primate cardiac xenotransplantation. 
  • Defective release of tissue plasminogen activator in patients with sickle cell anemia. 
  • Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. 
  • Defective release of vascular plasminogen activator in patients with gynecologic malignancies. 
  • Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke. 
  • Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. 
  • Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial infarction. TAMI-5 Study Group. 
  • Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. 
  • Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. 
  • Differences in Acute Ischemic Stroke Quality of Care and Outcomes by Primary Stroke Center Certification Organization. 
  • Distinguishing between early and late responders to symptoms of acute myocardial infarction. 
  • Do the investigative sites that take part in a positive clinical trial translate that evidence into practice? 
  • Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. 
  • Dysphagia in the setting of left ventricular assist device hemolysis. 
  • Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. 
  • Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. 
  • Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. 
  • Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. 
  • Editorial comment--what can models teach us about stroke treatment? Sorting out the missing bits. 
  • Effect of age on outcome with primary angioplasty versus thrombolysis. 
  • Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. 
  • Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. 
  • Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. 
  • Effectiveness and safety of abciximab after failed thrombolytic therapy. 
  • Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. 
  • Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation. 
  • Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction. 
  • Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy. 
  • Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. 
  • Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. 
  • Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). 
  • Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. 
  • Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. 
  • Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction. 
  • Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke. 
  • Emergency medical services use and its association with acute ischaemic stroke evaluation and treatment in Singapore. 
  • Emergency medicine in the Veterans Health Administration-results from a nationwide survey. 
  • Endovascular stroke intervention in young patients with large vessel occlusions. 
  • Endovascular treatment of venous sinus thrombosis: a case report and review of the literature. 
  • Epidemiology of a large telestroke cohort in the Delaware valley. 
  • Epidermal plasminogen activator is abnormal in cutaneous lesions. 
  • Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. 
  • Evaluation of Rescue Thrombolysis in Cardiac Arrest Secondary to Suspected or Confirmed Pulmonary Embolism. 
  • Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat. 
  • Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction. 
  • Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group. 
  • Experience with the use of tPA in the treatment of acute myocardial infarction. 
  • Expression of plasminogen activator enzymes in psoriatic epidermis. 
  • Expression of plasminogen activators in basal cell carcinoma. 
  • Facilitated PCI in patients with ST-elevation myocardial infarction. 
  • Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. 
  • Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. 
  • Facilitated versus primary PCI for acute myocardial infarction. 
  • Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. 
  • Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. 
  • Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. 
  • Favorable early and long-term prognosis following coronary bypass surgery therapy for myocardial infarction: results of a multicenter trial. TAMI Study Group. 
  • Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. 
  • Fibrinolytic abnormalities in two different cutaneous manifestations of venous disease. 
  • Filtering bleb thrombolysis with tissue plasminogen activator. 
  • Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. 
  • Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. 
  • Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. 
  • Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. 
  • From thrombolytic megatrials to clinical policy-making: facing the facts. 
  • Gender and acute myocardial infarction: is there a different response to thrombolysis? 
  • Global utilization of streptokinase and tPA for occluded arteries (GUSTO) ECG-monitoring substudy. Study design and technical considerations. 
  • Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. 
  • Graded exercise testing following thrombolytic therapy for acute myocardial infarction: the importance of timing and infarct location. TPAT Study Group. 
  • Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy. 
  • Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage. 
  • Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries. 
  • Helicopter transport of patients during acute myocardial infarction. 
  • Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. 
  • Hemostasis and alterations of the central nervous system. 
  • Heparin oligosaccharides enhance tissue-type plasminogen activator: a correlation between oligosaccharide length and stimulation of plasminogen activation. 
  • Heuristic and logistic principles of ST-segment interpretation in the time domain. Evolution in the context of the TAMI 7 trial design. 
  • High dose factor VIIa improves clot structure and stability in a model of haemophilia B. 
  • Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Hospital Factors Associated With Interhospital Transfer Destination for Stroke in the Northeast United States. 
  • Hospital arrival time and intravenous t-PA use in US Academic Medical Centers, 2001-2004. 
  • Hospital distance, socioeconomic status, and timely treatment of ischemic stroke. 
  • Hyperdense posterior cerebral artery sign in a setting of spontaneous vertebral artery dissection: a blessing in disguise? 
  • IV tPA for acute ischemic stroke: Times are changing. 
  • Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. 
  • Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. 
  • Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group. 
  • Importance of ST-segment depression as a determinant of ventricular premature complex frequency after thrombolysis for acute myocardial infarction. Tissue Plasminogen Activator: Toronto (TPAT) Study Group. 
  • Importance of early and complete reperfusion to achieve myocardial salvage after thrombolysis in acute myocardial infarction. 
  • Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. 
  • Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative. 
  • Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries. 
  • Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. 
  • Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. 
  • Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. 
  • Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis. 
  • Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience. 
  • Induction of tissue-type plasminogen activator and 72-kDa type-IV collagenase by ionizing radiation in rat astrocytes. 
  • Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. 
  • Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? 
  • International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. 
  • Intestinal Alkaline Phosphatase Attenuates Alcohol-Induced Hepatosteatosis in Mice. 
  • Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. 
  • Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial. 
  • Intravenous Fibrinolysis for Central Retinal Artery Occlusion: A Cohort Study and Updated Patient-Level Meta-Analysis. 
  • Intravenous Tissue Plasminogen Activator in Stroke Mimics. 
  • Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus. 
  • Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial. 
  • Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. 
  • Intravenous tissue plasminogen activator administration in community hospitals facilitated by telestroke service. 
  • Intravenous tissue-type plasminogen activator therapy is an independent risk factor for symptomatic intracerebral hemorrhage after carotid endarterectomy. 
  • Intravitreal clearance of tissue plasminogen activator in the rabbit. 
  • Intravitreal tissue plasminogen activator for the treatment of central retinal vein occlusion. 
  • Ionic modulation of the effects of heparin on plasminogen activation by tissue plasminogen activator: the effects of ionic strength, divalent cations, and chloride. 
  • Is the use of t-PA as compared with streptokinase cost effective? 
  • Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. 
  • Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. 
  • Isolation, culture, and characterization of endothelial cells from Schlemm's canal. 
  • Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation. 
  • Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study Group. 
  • Lack of impact of electronic health records on quality of care and outcomes for ischemic stroke. 
  • Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators) 
  • Late restenosis after emergent coronary angioplasty for acute myocardial infarction: comparison with elective coronary angioplasty. 
  • Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. 
  • Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. 
  • Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. 
  • Linkage analysis of peripheral neurofibromatosis to DNA markers on chromosome 8. 
  • Lipid profile, lipid-lowering medications, and intracerebral hemorrhage after tPA in get with the guidelines-stroke. 
  • Lipoprotein (a) regulates plasmin generation and inhibition. 
  • Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction. 
  • Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. 
  • Lipoprotein(a) inhibits plasminogen activation in a template-dependent manner. 
  • Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. 
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. 
  • Low-dose intraocular tissue plasminogen activator for treatment of postvitrectomy fibrin formation. 
  • Massive pulmonary embolism during pregnancy successfully treated with recombinant tissue plasminogen activator: a case report and review of treatment options. 
  • Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study. 
  • Medication, reperfusion therapy and survival in a community-based setting of hospitalised myocardial infarction. 
  • Medicine. Stroke--tPA and the clinic. 
  • Minding the stroke business. 
  • Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. 
  • Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain. 
  • Modulation of plasminogen activation and type IV collagenase activity by a synthetic peptide derived from the laminin A chain. 
  • Modulation of tissue plasminogen activator-catalyzed plasminogen activation by synthetic peptides derived from the amino-terminal heparin binding domain of fibronectin. 
  • More on the GUSTO Trial. 
  • More on the GUSTO trial. 
  • Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. 
  • Multimodal endovascular management of acute ischemic stroke in patients over 75 years old is safe and effective. 
  • Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Myelin basic protein stimulates plasminogen activation via tissue plasminogen activator following binding to independent l-lysine-containing domains. 
  • Myocardial infarction with minimal coronary atherosclerosis in the era of thrombolytic reperfusion. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. 
  • Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction. 
  • Nonlocalized lower gastrointestinal bleeding: provocative bleeding studies with intraarterial tPA, heparin, and tolazoline. 
  • North Carolina stroke prevention and treatment facilities survey: rtPA therapy for acute stroke. 
  • One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. 
  • One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial. 
  • One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. 
  • Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. 
  • Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. 
  • Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. 
  • Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. 
  • Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. 
  • Ozone exposure is associated with acute changes in inflammation, fibrinolysis, and endothelial cell function in coronary artery disease patients. 
  • PCI at non-PCI centres: immediate or rescue? 
  • Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. 
  • Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group. 
  • Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. 
  • Patient safety in trials of therapy for acute ischemic stroke. 
  • Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke. 
  • Percutaneous interventions on the hemodialysis reliable outflow vascular access device. 
  • Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction. 
  • Peripheral vascular complications during transcatheter aortic valve replacement: management and potential role of chronic steroid use. 
  • Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. 
  • Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. 
  • Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor. 
  • Platelet function and fibrinolytic agents: two sides of a coin? 
  • Polynitrosylated proteins: characterization, bioactivity, and functional consequences. 
  • Postoperative fibrin formation and visual outcome after pars plana vitrectomy. 
  • Precordial ST segment depression predicts a worse prognosis in inferior infarction despite reperfusion therapy. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. 
  • Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. 
  • Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. 
  • Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: a qualitative and quantitative angiographic study. 
  • Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. 
  • Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. 
  • Predictors of rapid brain imaging in acute stroke: analysis of the Get With the Guidelines-Stroke program. 
  • Predictors of symptomatic intracranial haemorrhage in patients with an ischaemic stroke with neurological deterioration after intravenous thrombolysis. 
  • Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America. 
  • Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. 
  • Primary angioplasty or thrombolysis for acute myocardial infarction? 
  • Prior Antithrombotic Use Is Associated With Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke. 
  • Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. 
  • Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. 
  • Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction. The TAMI Study Groups. 
  • Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. 
  • Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patients. 
  • Prognostic value of clinical markers of reperfusion in patients with acute myocardial infarction treated by thrombolytic therapy. 
  • Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy. 
  • Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. 
  • Prosthetic valve thrombosis: when and how should we lyse? 
  • Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. 
  • Provocative mesenteric angiography for lower gastrointestinal hemorrhage: results from a single-institution study. 
  • Pulmonary artery thrombus in a premature neonate treated with recombinant tissue plasminogen activator. 
  • Quality of Care and Outcomes for Patients With Stroke in the United States Admitted During the International Stroke Conference. 
  • Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. 
  • Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. 
  • Ratio of ST-segment and myoglobin slopes to estimate myocardial salvage during thrombolytic therapy for acute myocardial infarction. 
  • Re: Nonlocalized lower gastrointestinal bleeding: provocative bleeding studies with intraarterial tPA, heparin, and tolazoline. 
  • Recalibrating Reperfusion Waypoints. 
  • Recent Myocardial Infarction is Associated With Increased Risk in Older Adults With Acute Ischemic Stroke Receiving Thrombolytic Therapy. 
  • Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion. 
  • Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. 
  • Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo. 
  • Redefining Early Neurological Improvement After Reperfusion Therapy in Stroke. 
  • Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial. 
  • Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Regulation of plasminogen activation by components of the extracellular matrix. 
  • Regulation of tissue plasminogen activator in sickle cell anemia. 
  • Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. 
  • Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators. 
  • Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. 
  • Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. 
  • Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. 
  • Releasable vascular plasminogen activator and thrombotic strokes. 
  • Release of tissue plasminogen activator and its fast-acting inhibitor in defective fibrinolysis. 
  • Renal Dysfunction and In-Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy. 
  • Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. 
  • Reperfusion in waiting: what queue should we join? 
  • Rescue thrombolysis: resolution of intraglomerular thrombi after donation after circulatory death. 
  • Reteplase but not alteplase affects early soluble PECAM-1 and P-selectin release in patients with acute myocardial infarction. 
  • Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). 
  • Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. 
  • Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. 
  • Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. 
  • Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. 
  • Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. 
  • Routine 24-Hour Computed Tomography Brain Scan is not useful in stable patients Post Intravenous Tissue Plasminogen Activator. 
  • S-nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme. 
  • ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. 
  • ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. 
  • Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke. 
  • Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion. 
  • Safety of Computed Tomographic Angiography in the Evaluation of Patients With Acute Stroke: A Single-Center Experience. 
  • Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. 
  • Saline vs Tissue Plasminogen Activator Irrigations after Drain Placement for Appendicitis-Associated Abscess: A Prospective Randomized Trial. 
  • Screening with MRI for Accurate and Rapid Stroke Treatment: SMART. 
  • Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. 
  • Selection of reperfusion therapy for individual patients with evolving myocardial infarction. 
  • Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. 
  • Selective infusion of thrombolytic therapy in the acute myocardial infarct-related coronary artery as an alternative to rescue percutaneous transluminal coronary angioplasty. 
  • Sialic acid content of plasminogen 2 glycoforms as a regulator of fibrinolytic activity. Isolation, carbohydrate analysis, and kinetic characterization of six glycoforms of plasminogen. 
  • Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. 
  • Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. 
  • Soluble vascular cell adhesion molecule-1 and E-selectin in patients with acute myocardial infarction treated with thrombolytic agents. 
  • Stability of recombinant tissue plasminogen activator. 
  • Statewide assessment of hospital-based stroke prevention and treatment services in North Carolina: changes over the last 5 years. 
  • Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke. 
  • Streptokinase versus alteplase in acute myocardial infarction. 
  • Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. 
  • Superficial migratory thrombophlebitis and factor XII deficiency. 
  • Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. 
  • Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. 
  • Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. 
  • Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. 
  • Symbiotic relationship of IV-tPA and mechanical thrombectomy in a case of acute tandem ICA-MCA occlusion. 
  • Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin. 
  • Systemic hemostasis with recombinant-activated factor VII followed by local thrombolysis with recombinant tissue plasminogen activator in intraventricular hemorrhage. 
  • TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. 
  • Targeting telestroke: benchmarking time performance in telestroke consultations. 
  • Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. 
  • The effect of substituted laminin A chain-derived peptides on the conformation and activation kinetics of plasminogen. 
  • The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. 
  • The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. 
  • The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. 
  • The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis. 
  • The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention. 
  • The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a). 
  • The irony of biased editors who write editorials. GUSTO Investigators. 
  • The platelet-related effects of tenecteplase versus alteplase versus reteplase. 
  • The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? 
  • The risk of stroke after thrombolytic therapy. 
  • The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • The voltage-dependent anion channel (VDAC) binds tissue-type plasminogen activator and promotes activation of plasminogen on the cell surface. 
  • Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. 
  • Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality. 
  • Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. 
  • Thrombolysis and angioplasty in acute myocardial infarction. 
  • Thrombolysis for acute ischemic stroke in patients with cancer: a population study. 
  • Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo. 
  • Thrombolysis in young adults with stroke: Findings from Get With The Guidelines-Stroke. 
  • Thrombolysis is an Independent Risk Factor for Poor Outcome After Carotid Revascularization. 
  • Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Thrombolytic therapy for acute myocardial infarction: GUSTO criticized. 
  • Thrombolytic therapy for elderly patients. 
  • Thrombolytic therapy for myocardial infarction. 
  • Thrombolytic therapy for myocardial infarction: a perspective of clinical trialists. The GUSTO Investigators. 
  • Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices. 
  • Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Thrombolytic therapy of acute ischemic stroke: correlation of angiographic recanalization with clinical outcome. 
  • Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. 
  • Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. 
  • Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. 
  • Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. 
  • Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial. 
  • Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. 
  • Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. 
  • Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries. 
  • Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. 
  • Timely Reperfusion in Stroke and Myocardial Infarction Is Not Correlated: An Opportunity for Better Coordination of Acute Care. 
  • Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis. 
  • Tissue plasminogen activator and thrombin generation measurements using the Thrombinoscope. 
  • Tissue plasminogen activator contributes to morphine tolerance and induces mechanical allodynia via astrocytic IL-1β and ERK signaling in the spinal cord of mice. 
  • Tissue plasminogen activator for acute ischemic stroke. 
  • Tissue plasminogen activator for postvitrectomy fibrin formation. 
  • Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil. 
  • Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. 
  • Tissue plasminogen activator in a vertebral artery dissection. 
  • Tissue plasminogen activator in psoriasis. 
  • Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. 
  • Tissue plasminogen activator: why the backlash? 
  • Translational research in acute central nervous system injury: lessons learned and the future. 
  • Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. 
  • Treating myocardial infarction in the post-GUSTO era. A US perspective. 
  • Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population. 
  • Treatment of acute myocardial infarction. 
  • Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. 
  • Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator. 
  • Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. 
  • Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. 
  • Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. 
  • Ultramicrosurgical removal of subretinal hemorrhage in cats. 
  • Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X. 
  • Unmasking Proteolytic Activity for Adult Visual Cortex Plasticity by the Removal of Lynx1. 
  • Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age. 
  • Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. 
  • Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke. 
  • Use of a vascular reconstruction device to salvage acute ischemic occlusions refractory to traditional endovascular recanalization methods. 
  • Use of emergency department transcranial Doppler assessment of reperfusion after intravenous tPA for ischemic stroke. 
  • Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). 
  • Usefulness of a pericardial friction rub after thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage. The TAMI Study Group. 
  • Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect? 
  • Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences? 
  • Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey. 
  • Who should have a routine early invasive approach after fibrinolytic therapy? 
  • [Canadian Consensus Conference on Coronary Thrombolysis--current aspects]. 
  • mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. 
  • tPA-mediated generation of plasmin is catalyzed by the proteoglycan NG2. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Fekrat, Sharon, Professor of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • James, Michael Lucas, Associate Professor of Anesthesiology, Anesthesiology, Neuroanesthesia
  • Kim, Charles Yoon, Associate Professor of Radiology, Radiology, Interventional Radiology
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Innovation & Entrepreneurship
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Toth, Cynthia Ann, Joseph A.C. Wadsworth Distinguished Professor of Ophthalmology, Biomedical Engineering
  • Warner, David Samuel, Distinguished Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology